Treating Asthma with Monoclonal Antibody Based Drugs: Past Experience and Future Prospects
Respiratory diseases such as asthma and COPD (chronic obstructive pulmonary disease) are becoming more common, especially in children and the demand for continued advancements in drug discovery has grown significantly in recent years. It is estimated that the commercial drug development market will grow to $23 billion by 2014, with 300 million people in the world suffering from asthma.
Dr. Matthew Catley, Head of Respiratory Pharmacology at UCB, shares his insights on treating asthma with monoclonal antibody based drugs at IQPC's 2nd Asthma & COPD conference in June 2010.
- Examining asthma as a complex inflammatory disease of the lungs involving multiple cells and inflammatory mediators
- Displaying how mAbs can be targeted to neutralise cytokines, block cell activation or deplete pathogenic cells
- Exploring past pre-clinical and clinical experience of mAbs for the treatment of asthma
- Presenting a close examination of the clinical testing of anti IL-5 and TNFa to investigate why these entities have failed in the clinic for the treatment of asthma
- Identifying lessons learned regarding future antibody based therapies